References


References


References


doxorubicin (Caelyx) in combination with carboplatin in patients with

Gonzalez-Martin AJ, Calvo E, Bover I, et al. (2005). Randomized phase II trial of
carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent
advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en

epithelial ovarian carcinoma: a randomized phase III study of pegylated

Gordon AN, Granai CO, Rose PG, et al. (2000). Phase II study of liposomal doxorubicin
in platinum- and paclitaxel-refractory epithelial ovarian cancer. *J Clin
Oncol.* 18(17):3093-3100.

Long-term survival advantage for women treated with pegylated liposomal
doxorubicin compared with topotecan in a phase 3 randomized study of recurrent

with single-agent carboplatin in patients with epithelial ovarian cancer. London


of the ovary with cisplatin or carboplatin following initial treatment with these
compounds. *Gynecol Oncol.* 36(2):207-211.

Grambsch PM, Therneau TM (1994). Proportional hazards tests and diagnostics

Green S, Weiss GR (1992). Southwest Oncology Group standard response criteria,

phocytic leukemia after therapy with alkylating agents for ovarian cancer:

Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE (1983). Plasma pharma-
cokinetcis of adriamycin and adriamycinol: implications for the design of

Greer BE, Bundy BN, Ozols RF, et al. (2005). Implications of second-look laparot-
onomy in the context of optimally resected stage III ovarian cancer: a non-


References


Krafft W, Morack G, Flach W, et al. (1980). The therapy of the early ovarian cancer (T1/T2 M0 N0) (author’s transl) [in German]. Arch Geschwulstforsch. 50(7):664-671.


References


Markman M, Bundy BN, Alberts DS, et al. (2001). Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-


References


Oza AM, Cook AD, Pfisterer J, et al.; ICON7 trial investigators (2015). Standard chemotherapy with or without bevacizumab for women with newly diagnosed...
References


References


References


References

tion for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovar-

Trope C, Kaern J, Hogberg T, et al. (2000). Randomized study on adjuvant chemo-
therapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as

improved reference for grading the acute effects of cancer treatment: impact

ity and unique toxicities during two complementary phase I studies. J Clin
Oncol. 13(7):1777-1785.

cacy of pyridoxine to ameliorate the cutaneous toxicity associated with
doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-

van der Burg ME, Hoff AM, van Lent M, Rodenburg CJ, van Putten WL, Stoter G
(1991). Carboplatin and cyclophosphamide salvage therapy for ovarian can-
cer patients relapsing after cisplatin combination chemotherapy. Eur J Can-
cer. 27(3):248-250.

after induction chemotherapy on the prognosis in advanced epithelial ovarian
cancer. Gynecological Cancer Cooperative Group of the European Organiza-

ygy of carboplatin administered in combination with paclitaxel. Semin Oncol.

Vasey PA, Jayson GC, Gordon A, et al.; Scottish Gynaecological Cancer Trials
Group (2004). Phase III randomized trial of docetaxel-carboplatin versus
paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl
Cancer Inst. 96(22):1682-1691.

of differentiation and cyst rupture in stage I invasive epithelial ovarian carci-

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian
carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 71(3):
431-436.

Vergote I, Finkler N, del Campo J, et al. (2009). Phase 3 randomised study of can-
fosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topo-


